Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

In Vivo Molecular Imaging With Infliximab Antibody With FITC Predicts Therapeutic Response in Ulcerative Colitis

NCT02852850 is registered in ClinicalTrials.gov with Shandong University as lead sponsor.

NCT NCT02852850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02852850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
In Vivo Molecular Imaging With Infliximab Antibody With FITC Predicts Therapeutic Response in Ulcerative Colitis
Lead sponsor
Shandong University
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2016
Completion date
Not reported
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis